Preventive efficacy of six monthly doses of NexGard® PLUS or Simparica Trio® against a macrocyclic lactone-resistant isolate (JYD-34) of Dirofilaria immitis and of a single dose of NexGard PLUS against a susceptible isolate
The results of study 1 demonstrated that NexGard® PLUS and Simparica Trio® administered at the label dose provided comparable efficacy against a macrocyclic lactone-resistant isolate of D. immitis. The results of study 2 demonstrated that NexGard® PLUS administered once near the minimum label dose was 100% effective against a susceptible isolate.
Authors
- Joseph B. Prullage
- Justin Frost
- Utami DiCosty
- Élizabeth Martin (ORCID: https://orcid.org/0000-0002-0334-9916)
- Pascal Dumont
- Stephen Yoon
- Ricarda Süssenberger
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (United States) (US)
Publication Details
- Journal
- Parasites & Vectors
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s13071-024-06603-z
- Citations
- 2
- Primary Topic
- Parasitic Diseases Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.78